AI Models for Protein Design Are Driving Antibody Engineering
Overview
Authors
Affiliations
Therapeutic antibody engineering seeks to identify antibody sequences with specific binding to a target and optimized drug-like properties. When guided by deep learning, antibody generation methods can draw on prior knowledge and experimental efforts to improve this process. By leveraging the increasing quantity and quality of predicted structures of antibodies and target antigens, powerful structure-based generative models are emerging. In this review, we tie the advancements in deep learning-based protein structure prediction and design to the study of antibody therapeutics.
What does AlphaFold3 learn about antigen and nanobody docking, and what remains unsolved?.
Hitawala F, Gray J bioRxiv. 2025; .
PMID: 39975279 PMC: 11838198. DOI: 10.1101/2024.09.21.614257.
Nguyen V, Nguyen N, Hy T Struct Dyn. 2024; 11(6):064102.
PMID: 39629167 PMC: 11614476. DOI: 10.1063/4.0000271.
ABodyBuilder3: improved and scalable antibody structure predictions.
Kenlay H, Dreyer F, Cutting D, Nissley D, Deane C Bioinformatics. 2024; 40(10).
PMID: 39363504 PMC: 11474105. DOI: 10.1093/bioinformatics/btae576.
AI-driven antibody design with generative diffusion models: current insights and future directions.
He X, Li J, Xu J, Shan H, Shen S, Gao S Acta Pharmacol Sin. 2024; 46(3):565-574.
PMID: 39349764 PMC: 11845702. DOI: 10.1038/s41401-024-01380-y.
A survey of generative AI for de novo drug design: new frontiers in molecule and protein generation.
Tang X, Dai H, Knight E, Wu F, Li Y, Li T Brief Bioinform. 2024; 25(4).
PMID: 39007594 PMC: 11247410. DOI: 10.1093/bib/bbae338.